Visual Outcomes and Patient Satisfactory After PanOptix Implantation in Hyperopic Cataract Patients
Evaluation of Visual Outcomes and Patient Satisfactory After PanOptix Implantation in Hyperopic Cataract Patients: a Prospective, Cohort Study
1 other identifier
observational
44
0 countries
N/A
Brief Summary
To evaluate visual outcomes and patient satisfactory after PanOptix implantation in hyperopic cataract patients
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Feb 2023
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 22, 2023
CompletedStudy Start
First participant enrolled
February 1, 2023
CompletedFirst Posted
Study publicly available on registry
February 8, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2023
CompletedFebruary 8, 2023
February 1, 2023
9 months
January 22, 2023
February 4, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Best corrected distance visual acuity of the operated eye
Best corrected distance visual acuity (BCDVA) of the operated eye will be measured.
3 months postoperatively
Secondary Outcomes (7)
Uncorrected distance visual acuity (UCVA)
3 months postoperatively
Uncorrected intermediate visual acuity
3 months postoperatively
Uncorrected near visual acuity
3 months postoperatively
Best corrected intermediate visual acuity
3 months postoperatively
Best corrected near visual acuity
3 months postoperatively
- +2 more secondary outcomes
Eligibility Criteria
Hyperopic cataract patients receiving bilateral uneventful phacoemulsification and implantation of PanOptix.
You may qualify if:
- age-related cataract patients
- Eye axis length ≤22.5mm and refraction ≥ +0.5D
- Predicted postoperative corneal astigmatism ≤0.75D
- mesopic pupil size between 3.0mm to 5.5 mm
- Preoperative angle kappa ≤ 0.5 mm
- Preoperative corneal spherical aberration \<0.5μm, high order aberration \<0.5μm
You may not qualify if:
- In the presence of other ocular diseases that may affect the stability of the lens capsule (pseudoexfoliation syndrome, glaucoma, traumatic cataract, Marfan syndrome, etc.)
- Pupil abnormality (non-reactive pupil, tonic pupils, abnormally shaped pupils, etc.)
- History of any clinically significant retinal pathology or ocular diagnosis (e.g. diabetic retinopathy, ischemic diseases, macular degeneration, retinal detachment, optic neuropathy optic nerve atrophy, amblyopia, strabismus, microphthalmos, aniridia, epiretinal membrane etc.) in the study eyes that could alter or limit final postoperative visual prognosis
- Patients with history of ocular trauma or prior ocular surgery including refractive procedures
- Preoperative visual acuity of worse than 0.2 logMAR in any eye.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Peking University Third Hospitallead
- Tianjin Eye Hospitalcollaborator
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hong Qi, MD, PhD
Peking University Third Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
January 22, 2023
First Posted
February 8, 2023
Study Start
February 1, 2023
Primary Completion
November 1, 2023
Study Completion
December 1, 2023
Last Updated
February 8, 2023
Record last verified: 2023-02